期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

弥漫性大B细胞淋巴瘤经利妥昔单抗联合化疗后进展伴CD_(20)抗原表达丢失1例报道并文献复习 被引量：3

下载PDF
导出
摘要 目的探讨B细胞恶性肿瘤利妥昔单抗(rituximab)治疗后进展伴CD20抗原表达丢失患者的生物学特性。方法分析1例弥漫大B细胞淋巴瘤利妥昔单抗联合化疗进展伴CD20抗原表达丢失及文献复习。结果1例45岁男性弥漫大B细胞淋巴瘤患者,初治时病理免疫组化(IHC):CD5-、CD20+、CD45RO-、CD10-、CycinD1弱表达。染色体46,XY。利妥昔单抗联合化疗达CR。利妥昔单抗维持治疗出现进展及白血病转化。流式细胞仪(FCAS)检测:CD19+、CD79a+、CD22+而CD20-;免疫组化(IHC)染色CD20个别阳性细胞;核型为46,XY。结论B细胞恶性肿瘤经利妥昔单抗治疗后进展可能与CD20抗原表达丢失有关,应重新进行病理组织学、免疫表型和细胞分子遗传学检测。
作者 冯兰英 俞建平
机构地区 浙江临安市人民医院
出处 《实用肿瘤杂志》 CAS 北大核心 2010年第2期188-190,共3页 Journal of Practical Oncology
关键词 淋巴瘤 大细胞 弥漫型 利妥昔单抗/药物疗法 CD20抗原
分类号 R733.1 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1邹德慧,赵耀中,李睿,林华,刘欣,钱林生,邱录贵.前体B细胞淋巴母细胞淋巴瘤/白血病美罗华联合化疗治疗后复发伴CD_(20)抗原表达丢失1例报道并文献复习[J].白血病．淋巴瘤,2005,14(4):208-211. 被引量：5
  • 2Cartron G, Watier H, Golay J, et al. From the bench to the bedside:ways to improve rituximab efficacy [ J ]. Blood, 2004,104 (9) :2635 - 2642.
  • 3British Commzttee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrornboeytopenic purpura in adtdts,children and in pregnancy [J]. Br J Haematol, 2003,120 (4) :574 - 596.
  • 4Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphom a with anti-CD20 antibodies can result in the loss of CD20 antigen expression [ J ]. Clin Cancer Res, 1999,5 (1) :611 -615.
  • 5Gokbuget N, Hoelzer D. Treatment with monoelonal antibodies in a-cute lymphoblastic leukemia: current knowledge and future prospects [ J]. Ann Hematol,2004, 83(12) :201 -205.
  • 6Coffier B, Lepage E, Briere PD, et al. CHOP chemotherapy plus rituximah compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma [ J ]. N Engl J Med ,2002,346 (4) :235 - 242.
  • 7Czuczman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low- grade or follicular non Hodgkin's lymphoma treated with rituximab pus CHOP chemotherapy 9 year follow-up [ J ]. J Clin Oncol,2004,22 (8) :4659 - 4668.
  • 8Stanglmater M, Reis S. Hallek M. Rituximab and alemtuzumab induce a nonctassic, easpase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells [ J ]. Ann Hematol. 2004,83 (10) :634 - 645.
  • 9Chu PG, Chen YY, Molina A, et al. Recurrent B-cell neoplasms after rituximab therapy an immunophenotypic and genotypic study [ J ]. Leukemia Lymphoma, 2002,43 (23) :2335 - 2341.
  • 10Alvaro-Naranjo T,Jaen-Martinez J, Guma-Padro J, et al. CD20 negative DLBCL transformation after rituximab treatment in follicular lymphoma a case report and review of the literature [ J ]. Ann Hematol, 2003,82 ( 18 ) : 585 - 588.

二级参考文献47

  • 1Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MINT) Group[J]. Lancet Oncol, 2006, 7(5): 379- 391.
  • 2Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de I'Adulte[J]. J Clin Oncol, 2005, 23(18): 4117-4126.
  • 3Coiffier B, Feugier P, Mounier N, et al. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients[Meeting Abstracts][J]. J Clin Oncol, 2007, 25 (18S): 8009.
  • 4Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD 10 B-cell lymphomas: a randomized controlled trial (RICOVER-60)[J]. Lancet Oncol, 2008, 9(2): 105- 116.
  • 5Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and eyelophosphamide, doxorubicin, vineristine, and prednisoue significantly improves response and time to treatment failure, but not long-term outcome in patients with previouslyuntreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)[J]. J Clin Oncol, 2005, 23(9):1984-1992.
  • 6Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as firstline and maintenance therapy for patients with indolent non-Hodgkin's lymphoma[J]. J Clin Oncol, 2002, 20(20): 4261-4267.
  • 7Ghiehnini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly×4 schedule[J]. Blood, 2004, 103(12): 4416- 4423.
  • 8Gordan LN, Grow WB, Pusateri A, et al. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders[J]. J Clin Oncol, 2005, 23(6): 1096- 1102.
  • 9Hagenbeek A, Van Glabbeke M, Teodorovic I, et al. The role of rituximab maintenance treatment in relapsed follicular NHL: in interim analysis of the EORTC randomized intergroup trial[Meeting Abstracts]. Ann Oncol, 2005, 16: v52. Abstract 61.
  • 10Morrison VA, Weller EA, Habermann TM, et al. Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): an Intergroup E4494/C9793 update[Meeting Abstracts]. J Clin Oncol. 2007, 25(18S): 8011.

共引文献12

同被引文献49

  • 1GUERARD E J, BISHOP MR. Overview of non-Hodgkin's lym- phoma[J]. Dis Mon,2012,58(4): 208 -218.
  • 2ZHENG RL,JIANG YJ,WANG X. Role of microRNAs on thera- py resistance in non-Hodgkin's lymphoma [ J ]. lnt J Clin Exp Med,2014,7( 11 ) : 3818 -3832.
  • 3MOTTA G,CEA M, MORAN E,et al. Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives [ J ]. Clin Dev lmmunol,2010,2010 : 428253.
  • 4ROBAK T. Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia [ J 1. Future 0ncol,2013,9(1) : 69 -91.
  • 5GOPAL AK, PRESS OW,WILBUR SM,et al. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radio- labeled anti-CD45 Ab [ J ]. Blood,2008,112 ( 3 ) : 830 - 835.
  • 6CARTRON G, WATIER H, GOLAY J, et al. From the bench to the bedside: ways to improve rituximab efficacy [ J ]. Blood,2004,104 (9) : 2635 - 2642.
  • 7MALONEY DG. Anti-CD20 antibody therapy for B-cell lympho- mas[J]. NEnglJMcd,2012,366(21): 2008 -2016.
  • 8O'CONNOR K,LIDDLE C. Prospective data collection of off-la- bel use of rituximab in Australian public hospitals [ J ]. Intern Med J,2013,43(8) : 863 -870.
  • 9KATTAH AG, FERVENZA FC. Rituximab: emerging treatment strategies of immune-mediated glomerular disease[ J]. Expert Rev Clin lmmunol,2012,8(5) : 413 -421.
  • 10LEMERY SJ,ZHANGJ,ROTHMANN MD,et al. U.S. Food and Drug Administration Approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludara- bine and alemtuzumab [ J]. Clln Cancer Res, 2010, 16 ( 17 ) : 4331 -4338.

引证文献3

二级引证文献2

实用肿瘤杂志
2010年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部